Maple Grove, Minn. – September 30, 2026 -- Upsher-Smith Laboratories, LLC has launched Fluvoxamine Maleate Extended-Release Capsules in 100 mg and 150 mg strengths, entering a U.S. market valued at approximately $44.6 million according to IQVIA data covering August 2025 through July 2026.